AHR vs CUBE

The deterministic health scores raise significant concerns, with a Piotroski F-Score of 4/9 indicating marginal financial stability and no available Altman Z-Score to confirm solvency. Despite strong recent price performance and a bullish analyst recommendation, the stock trades at extreme valuation multiples (P/E of 385 and Forward P/E of 65), far above sector averages, while profitability remains weak (ROE: 1.10%, ROA: 2.15%). The dividend is dangerously overfunded with an 833% payout ratio, and insider activity is uniformly bearish, with $3.88M in net sales over the past six months. Although revenue growth and recent earnings surprises are positive, these do not justify the current premium given underlying financial fragility.

CUBE exhibits significant valuation misalignment and deteriorating financial fundamentals. The deterministic baseline is weak, with a Piotroski F-Score of 4/9 (Stable/Weak) and a current price of $39.54 that vastly exceeds both the Graham Number ($19.83) and the Intrinsic Value ($10.22). Most concerning is the unsustainable dividend payout ratio of 143.15% coupled with a -21.70% YoY decline in earnings growth. With zero earnings beats in the last four quarters and bearish insider activity, the stock appears heavily overvalued.